Stock Alert: INOVIO Shares Up 14% In Premarket On COVID-19 Vaccine DNA Data

(RTTNews) - Shares of INOVIO (INO) are rising over 14% in pre-market today, after the company announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2.

The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a DNA vaccine candidate for COVID-19" by INOVIO scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University, and Advaccine.

INO-4800 is INOVIO's DNA vaccine candidate created to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. INO-4800 was designed using INOVIO's proprietary DNA medicine platform rapidly after the publication of the genetic sequence of the coronavirus that causes COVID-19.

The stock has been trading in the range of $1.92 - $19.36 for the past one year, and closed Tuesday's trade at $14.56, up 39 cents or 2.75%. INO is currently trading at $16.72, up $2.16 or 14.84% in the pre-market session.